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Purpose: To identify the incidence, preoperative risk factors, and prognosis associated
with pathologically positive lymph node (pN+) in patients undergoing a sub-lobar
resection (SLR).
Methods: This is a retrospective study using the National Cancer Database (NCDB) from
2004 to 2014 analyzing SLR excluding those with any preoperative chemotherapy and/or
radiation, follow-up <3 months, stage IV disease, or >1 tumor nodule. Multivariable
modeling (MVA) was used to determine factors associated with overall survival (OS).
Propensity score matching (PSM) was used to determine preoperative risk factors for
pN+ in patients having at least one node examined to assess radiation’s effect on OS in
those patients with pN+ and to determine whether SLR was associated with inferior OS
as compared to lobectomy for each nodal stage.
Results: A total of 40,202 patients underwent SLR, but only 58.3% had one lymph node
examined. Then, 2,615 individuals had pN+ which decreased progressively from 15.1%
in 2004 to 8.9% in 2014 (N1, from 6.3 to 3.0%, and N2, from 8.4 to 5.9%). A lower risk
of pN+ was noted for squamous cell carcinomas, bronchioloalveolar adenocarcinoma
(BAC), adenocarcinomas, and right upper lobe locations. In the pN+ group, OS was
worse without chemotherapy or radiation. Radiation was associated with a strong trend
for OS in the entire pN+ group (p= 0.0647) which was largely due to the effects on those
having N2 disease (p = 0.009) or R1 resections (p = 0.03), but not N1 involvement
(p = 0.87). PSM noted that SLR was associated with an inferior OS as compared
to lobectomy by nodal stage in the overall patient population and even for those with
tumors <2 cm.
Varlotto et al. Incidence and Outcomes of SLRs With Positive Nodes
Conclusion: pN+ incidence in SLRs has decreased over time. SLRwas associated with
inferior OS as compared to lobectomy by nodal stage. Radiation appears to improve the
OS in patients undergoing SLR with pN+, especially in those with N2 nodal involvement
and/or positive margins.
Keywords: sub-lobar resection (SLR), radiation, node positive, incidence, lung cancer
INTRODUCTION
In 1995, a landmark investigation by the Lung Cancer Study
Group demonstrated that sub-lobar resection (SLR) was inferior
to lobectomy (tumor size <3 cm), reporting an increase in
recurrence and trend toward decreased survival in patients
undergoing SLR for non-small-cell lung cancer (NSCLC) (1).
Subsequently, SLRs are often reserved for patients who cannot
tolerate larger pulmonary resection (e.g., lobectomy) due to
marginal pulmonary function tests and other comorbidities.
Although there are several different definitions of adequate
lymph node dissection (2), none pertains particularly to patients
undergoing SLR.
Even with clinical stage I NSCLC in the era of PET-CT staging,
past reports have indicated that as many as 10–20% of patients
may have microscopic nodal involvement (3–6). Unfortunately,
as many as 40–70% of patients undergoing SLR have not had a
single lymph node removed or examined (7–10). Nevertheless,
one recent retrospective review using the SEER database noted
a lung cancer-specific survival (LCSS) and overall survival (OS)
benefit with more extensive lymph node dissection in patients
who received a sub-lobar excision (11).
The purpose of our study is to identify preoperative factors
associated with lymph node involvement so that it could be
better understood which patients would preferentially benefit
from a lymphadenectomy and to assess whether patients with
pathologically positive lymph nodes (pN+) may benefit from
radiation therapy. We investigate the incidence of pN+ in
patients undergoing SLR and whether SLR was associated with
inferior OS in patients with pN+.
METHODS
Data for this study were derived from the National Cancer
Database (NCDB) registry for patients diagnosed between 2004
and 2014. The NCDB currently captures 70% of all newly
diagnosed malignancies in the United States annually. The
patient information was de-identified. Thus, this investigation
was exempted from institutional review board (IRB) approval.
Individuals included were those undergoing SLR (sub-lobar
NOS, wedge resection, segmentectomy) for stages I–III NSCLC.
We also included patients undergoing (bi)lobectomy (N =
107,193) for the propensity score matching (PSM) to patients
undergoing SLR so that the OS could be compared for each nodal
level depending upon surgical resection. Exclusion criteria were
any preoperative chemotherapy and/or radiation, follow-up <3
months, stage IV disease, >1 tumor nodule, or missing data on
the timing of adjuvant therapy. To ensure that patients were
receiving adjuvant and not salvage radiation, chemotherapy or
postoperative radiation (PORT) had to be initiated within 120
days of surgery. PORT was permitted to start within 240 days
after surgery if chemotherapy was started within the 120-day
interval of surgery. Full selection criteria can be seen in Figure
4 in the Supplementary Material.
The outcomes were (a) pN+ involvement and (b) OS in those
with lymph node involvement.
To identify the factors associated with pathologic lymph
node involvement (among those who had any lymph node
examined), it was performed as a bivariate and multivariate
analysis considering the following variables: age, sex, race
(non-Hispanic white, white Hispanic, black, other), location
[right upper lobe (RUL), right middle lobe (RML), right lower
lobe (RLL), left upper lobe (LUL), left lower lobe (LLL),
other, NOS], histology [adenocarcinoma, bronchioloalveolar
adenocarcinoma (BAC), adenosquamous cell carcinoma, large
cell carcinoma, NSCLC NOS, squamous cell carcinoma],
facility type (community program, academic research institute,
comprehensive community cancer program, integrated), facility
location (New England, East North Central, East South Central,
Middle Atlantic, Mountain, Pacific, South Atlantic, West
North Central, West South Central), insurance (unknown,
private, Medicaid, Medicare, no insurance, government), income
(<$38,000; $38,000–$48,000; >48,000–$63,000; >$63,000), area
(rural near or not near metropolitan area, metropolitan area
>1,000,000 population, metropolitan area > or <250,000, urban
> or <20,000 near metropolitan area, urban > or <20,000
not near metropolitan area), type of resection (segmentectomy,
wedge, sub-lobar NOS), Charlson comorbidity status as adapted
by Deyo et al. (12) and tumor size.
To assess the effect of radiation on OS in those with pN+,
all of the preoperative factors were considered. Additionally,
the following factors were included: surgical margins (R0
clear, R1 microscopically positive, R2 grossly positive),
lymphatic vascular invasion, tumor grade (well, moderate,
poor, undifferentiated/anaplastic), number of nodes examined,
number of pN+, radiation dose, chemotherapy, hospital
readmission, length of stay, and T/N stage. These same factors
for OS were also used in the PSM comparing lobectomy vs. SLR
per N stage.
Terminology
1. pN+ or node involvement or positive nodes refers
to pathologic node involvement regardless of clinical
enlargement, i.e., enlarged CT and/or fluorodeoxyglucose
(FDG) avid.
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2. cN+ refers to clinically enlarged nodes regardless of
pathologic involvement. cN+ is the only term for clinical
involvement. Of note, some patients could have had biopsy-
positive nodes prior to surgical resection and be classified as
clinical node involvement as per NCDB staging rules.
STATISTICAL METHODS
The propensity match for the evaluation of factors predicting
pN+ was performed only in the patients who had at least
one node examined and clinically negative nodes. These
propensity scores were created through logistic regression [area
under the receiver operating characteristic (AUROC) = 0.8552]
and matched for type of surgical resection and number of
nodes examined.
The propensity match for comparison of the SLR and
lobectomy groups by node stage were matched by age,
sex, pathologic t-stage, number of nodes examined, number
of positive nodes, tumor size, histology group (squamous,
adenocarcinoma, and other), lymphovascular invasion (LVI), and
Charlson comorbidity status.
Multivariate analysis for OS was performed in the pN+
population using proportional hazard Cox regression.
The propensity scores to assess the effects of radiation on
the OS and the OS by surgical type by node stage were both
performed only on patients with pN+ and matched by factors
that were significant in the MVA for OS (age, sex, race, tumor
location, histology, facility type, facility location, insurance status,
income, urban/rural location, type of surgical resection, N stage,
and tumor size). The Toolkit for Weighting and Analysis of
Non-equivalent Groups (TWANG) macro was run in SAS to
create the propensity scores for this pathologically node-positive
group (13).
RESULTS
A total of 40,202 patients received SLR during the period
analyzed. Then, 23,440 patients (58.3%) had at least one lymph
node examined, and 2,615 of them were found to have pN+.
Of those having at least one node examined, the median
number of nodes examined was 4 (1–83), and 11.2% of patients
had positive nodes. Table 1 presents the percentage of patients
with pN+ per analyzed variable for patients having at least
one node examined. Facility type and location were significantly
associated with having positive nodes. Academic research
programs had a lower incidence of node involvement (10.28%)
as compared to community hospitals and integrated network
cancer programs (11.36–12.86%). Patients in New England had
the lowest incidence of node involvement (9.14%), while the west
south central area had the highest incidence of node involvement
(15.08%). Personal characteristics (age, sex, and race) were all
associated with node involvement. Patients who were younger
than 65 years had a higher rate of nodal positivity than older
(13.83 vs. 10.17%), while white non-Hispanic patients (10.82%)
had the lowest incidence of all races, and women had a lower
rate than men (10.48 vs. 12.01%). Both T stage and resection
type (R0, R1, R2) were associated with a significant rise in node
positivity with stage (T1, 8.93%; T2–T4, 18.45–18.27%), (R0,
10.09%; R1, 24.32%; R2, 34.11%). As differentiation decreased,
so did the percentage of patients with nodal positivity (3.87–
18.15%). Tumor size and lymphatic vascular invasion were
also significantly associated with nodal positivity. Histology was
significantly associated with nodal positivity with BAC (4.75%)
and squamous cell carcinoma (8.53%) having the lowest risk, and
large cell (16.16%) and NSCLC-NOS (18.44%) having the highest
risk. Charles Mayo score was inversely associated with nodal
positivity. Patients receiving their care through Medicare had the
lowest rate of positive nodes (10.02%). SLR-NOS had a much
greater rate of nodal positivity (19.1%) than segmentectomy
(10.62%) and wedge resection (11.02%). There was no significant
association with nodal positivity based upon geographic location
or income.
When clinically node-negative patients with (5.2% of these
patients) and without pathologic node involvement were
matched by PSM for type of resection and number of nodes
examined, the factors that were associated with pN+ are listed
by the factor and its associated odds ratio. Non-RUL locations
remained significantly associated with node involvement: LLL,
1.59 (1.28–1.97); LUL, 1.71 (1.42–2.06); RLL, 1.77 (1.44–2.17);
RML, 1.78 (1.20–2.64); and other locations, 2.50 (1.70–3.70).
Likewise, squamous cell carcinoma 0.51 (0.43–0.62) and BAC
0.34 (0.23–0.49) histologies were significantly less likely to have
node involvement, and tumor size was positively associated
with node involvement 1.02 (1.014–1.031). However, non-
traditional factors associated with nodal involvement included
comprehensive community cancer center vs. academic research
program, 1.18 (1.012–1.374), and white Hispanic vs. white non-
Hispanic ethnicity, 1.68 (1.11–2.54). A total of 762 patients
had clinical N1, 930 had clinical N2, and 82 had clinical N3
involvement, and the percentage of patients with pathologic
lymph node involvement was 64, 71, and 38%, respectively.
The OS of patients receiving SLR and at least one node
examined by node stage can be seen in Figure 1A. There
are 15,875, 793, 1,173, and 29 patients with N0, N1, N2,
and N3 nodes. Despite the inadequate surgical treatment of
the primary tumor, the OS still sharply decreased by node
stage. Figure 1B shows that OS by node stage is significantly
less for the SLR group compared to the lobectomy group
without propensity matching. After propensity matching, the
SLR group still has lower OS for the entire surgical population
(Figure 1C) and for the subset of patients with tumors <= 2 cm
(Figure 1D). See Supplementary Material for Figures S1B–D
including N3 nodes.
Table 2 demonstrates that the risk of patients having pN+
decreased during the years of our study from 2004 to 2014
in all node stages. The risk of any positive nodes (15.13–
8.88%) as well as N1 nodes (6.29–2.96%), N2 (8.43–5.86%), and
N3 (0.4–0.06%) all decreased during the years of our study.
Supplemental Table 2 notes the incidence of pN+ in patients
who are not cN+.
Multivariate analysis for OS for patients having pN+
can be seen in Table 3. Supplemental Table 3 includes the
MVA for OS in patients having only pN+ without cN+.
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Facility type Academic/Research program 10,235 9,183 (89.7%) 1,052 (10.3%) 0.0014
Community cancer program 1,376 1,199 (87.1%) 177 (12.9%)
Comprehensive community cancer program 9,636 8,503 (88.2%) 1,133 (11.8%)
Integrated network cancer program 2,148 1,904 (88.6%) 244 (11.4%)
Facility location East North Central 4,354 3,896 (89.5%) 458 (10.5%) < 0.0001
East South Central 1,767 1,543 (87.3%) 224 (12.7%)
Middle Atlantic 4,962 4,454 (89.8) 508 (10.2%)
Mountain 743 659 (88.7%) 84 (11.3%)
New England 1,784 1,621 (90.9%) 163 (9.1%)
Pacific 2,046 1,835 (89.7%) 211 (10.3%)
South Atlantic 5,104 4,497 (88.1%) 607 (11.9%)
West North Central 1,594 1,400 (87.8%) 194 (12.2%)
West South Central 1,041 884 (84.9%) 157 (15.1%)
Year of diagnosis 2004 747 634 (84.9%) 113 (15.1%) < 0.0001
2005 887 766 (86.4%) 121 (13.6%)
2006 986 838 (85.0%) 148 (15.0%)
2007 1,231 1,082 (87.9%) 149 (12.1%)
2008 2,070 1,814 (87.6%) 256 (12.4%)
2009 2,410 2,094 (86.9%) 316 (13.1%)
2010 2,647 2,343 (88.5%) 304 (11.5%)
2011 2,820 2,532 (89.8%) 288 (10.2%)
2012 3,002 2,686 (89.5%) 316 (10.5%)
2013 3,229 2,928 (90.7%) 301 (9.3%)
2014 3,411 3,108 (91.1%) 303 (8.9%)
Race Asian or Pacific Islander 359 311 (86.6%) 48 (13.4%) 0.0002
Black 1,706 1,483 (86.9%) 223 (13.1%)
Other/Unknown 1,500 1,330 (88.7%) 170 (11.3%)
White Hispanic 415 347 (83.6%) 68 (16.4%)
White Non-hispanic 19460 17354 (89.2%) 2106 (10.8%)
Primary payor Insurance status unknown 267 223 (83.5%) 44 (16.5%) < 0.0001
Medicaid 905 781 (86.3%) 124 (13.7%)
Medicare 16,104 14,491 (90.0%) 1,613 (10.0%)
Not insured 293 252 (86.0%) 41 (14.0%)
Other Government 167 142 (85.0%) 25 (15.0%)
Private insurance 5,704 4,936 (86.5%) 768 (13.5%)
Urban/Rural 2003 Completely rural or <2,500 urban population,
adjacent to a metro area
239 214 (89.5%) 25 (10.5%) 0.1172
Completely rural or <2,500 urban population,
not adjacent to a metro area
245 217 (88.6%) 28 (11.4%)
Counties in metro areas of 1 million population
or more
12,371 11,029 (89.2%) 1,342 (10.8%)
Counties in metro areas of 250,000–1 million
population
4,246 3,727 (87.8%) 519 (12.2%)
Counties in metro areas of fewer than 250,000
population
2,135 1,903 (89.1%) 232 (10.9%)
Urban population of 2,500–19,999, adjacent to
a metro area
1,268 1,106 (87.2%) 162 (12.8%)
Urban population of 2,500–19,999, not
adjacent to a metro area
637 575 (90.3%) 62 (9.7%)
Urban population of 20,000 or more adjacent
to a metro area
1,151 1,030 (89.5%) 121 (10.5%)
(Continued)
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Surgery type Segmentectomy 5,508 4,923 (89.4%) 585 (10.6%) < 0.0001
Sub-Lobar resection, NOS 665 538 (80.9%) 127 (19.1%)
Wedge resection 17,267 15,364 (89.0%) 1,903 (11.0%)
Tumor location Left lower lobe 3,508 3,157 (90.0%) 351 (10.0%) < 0.0001
Left upper lobe 7,064 6,143 (87.0%) 921 (13.0%)
Main bronchus 28 24 (85.7%) 4 (14.3%)
Other/NOS 638 534 (83.7%) 104 (16.3%)
Right lower lobe 4,272 3,795 (88.8%) 477 (11.2%)
Right middle lobe 706 612 (86.7%) 94 (13.3%)
Right upper lobe 7,224 6,560 (90.8%) 664 (9.2%)
Histology Adenocarcinoma 13,474 11,805 (87.6%) 1,669 (12.4%) < 0.0001
Adenosquamous 621 531 (85.5%) 90 (14.5%)
BAC 1,684 1,604 (95.2%) 80 (4.8%)
Large cell CA 724 607 (83.8%) 117 (16.2%)
Non-small-cell carcinoma, NOS 678 553 (81.6%) 125 (18.4%)
Squamous cell CA 6,259 5,725 (91.5%) 534 (8.5%)
T-Stage T1 17,971 16,366 (91.1%) 1,605 (8.9%) < 0.0001
T2 4,043 3,297 (81.6%) 746 (18.4%)
T3 720 585 (81.2%) 135 (18.8%)
T4 706 577 (81.7%) 129 (18.3%)
Surgical Margins R0 22,043 19,819 (89.9%) 2,224 (10.1%) < 0.0001
R1 699 529 (75.7%) 170 (24.3%)
R1 or R2 569 392 (68.9%) 177 (31.1%)
R2 129 85 (65.9%) 44 (34.1%)
Gender Female 13,082 11,711 (89.5%) 1,371 (10.5%) 0.0002
















Grade Cell type not determined, not stated or not
applicable, unknown primaries, high grade
dysplasia
1,500 1,307 (87.1%) 193 (12.9%) < 0.0001
Well-differentiated 3,796 3,649 (96.1%) 147 (3.9%)
Moderately differentiated, moderately
well-differentiated, intermediate differentiation
10,576 9,510 (89.9%) 1,066 (10.0%)
Poorly differentiated 7,287 6,129 (84.1%) 1,158 (15.9%)
Undifferentiated, anaplastic 281 230 (81.8%) 51 (18.2%)
Age <65 6,314 5,441 (86.2%) 873 (13.8%) < 0.0001
≥65 17,126 15,384 (89.8%) 1,742 (10.2%)
Tumor size <20mm 12,168 11,245 (92.4%) 923 (7.6%) < 0.0001
≥20mm 11,272 9,580 (85.0%) 1,692 (15.0%)
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FIGURE 1 | Continued
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D
FIGURE 1 | (A) OS by node stage in patients undergoing SLR. (B) OS by node stage by type of resection, sub-lobar vs. lobectomy, unmatched. Propensity match for
OS by node stage by type of resection for all resected tumors (C) and only for those <2 cm in size (D). All node stages are pathologic in this figure. (B–D) exclude N3
nodes for clarity. (B–D) Including N3 nodes are available in Supplementary Material.
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TABLE 2 | Percentage of patients with pathologically N1, N2, and N3 node involvement during years 2004–2014.
Year of diagnosis Total patients/Year N0 Freq (%) Total positive nodes per year (%) N1 Freq (%) N2 Freq (%) N3 Freq (%)
2004 747 634 (84.9) 113 (15.1) 47 (6.3) 63 (8.4) 3 (0.4)
2005 887 766 (86.4) 121 (13.6) 47 (5.3) 69 (7.8) 5 (0.6)
2006 986 838 (85.0) 148 (15.0) 71 (7.2) 76 (7.7) 1 (0.1)
2007 1,231 1,082 (87.9) 149 (12.1) 65 (5.3) 83 (6.7) 1 (0.1)
2008 2,070 1,814 (87.6) 256 (12.4) 108 (5.2) 142 (6.9) 6 (0.3)
2009 2,410 2,094 (86.9) 316 (13.1) 100 (4.2) 211 (8.8) 5 (0.2)
2010 2,647 2,343 (88.5) 304 (11.5) 117 (4.4) 180 (6.8) 7 (0.3)
2011 2,820 2,532 (89.8) 288 (10.2) 112 (4.0) 174 (6.2) 2 (0.1)
2012 3,002 2,686 (89.5) 316 (10.5) 122 (4.1) 190 (6.3) 4 (0.1)
2013 3,229 2,928 (90.7) 301 (9.3) 106 (3.3) 191 (5.9) 4 (0.1)
2014 3,411 3,108 (91.1) 303 (8.9) 101 (3.0) 200 (5.9) 2 (0.1)
Personal characteristics associated positively with OS include
younger age, female sex, Asian/Pacific Islander vs. non-
Hispanic white, and having a 0 for Charlson comorbidity
status. Histologic factors associated with survival included
tumor size, number of positive nodes, number of nodes
examined, higher T stage, poor differentiation, and lymphatic
vascular invasion. Treatment factors associated with OS
include not having radiation or chemotherapy and length
of stay.
A propensity match to assess the effects of radiation on OS
was performed only on patients with pN+ and matched by
factors that were significant in the MVA for OS (age, sex, race,
tumor location, histology, facility type, facility location, insurance
status, income, urban/rural location, type of surgical resection,
N stage, and tumor size). The standardized differences between
the patients receiving and not receiving radiation before and after
the match can be seen in Figure 2, demonstrating the successful
alignment of prognostic factors after the match. After propensity
matching, OS curves were generated for the entire population
and the subgroups with negativemargins and positivemargins, as
can be seen in Figures 3A–E. When an adequate radiation dose of
>44Gy was given, OS was significantly better in the entire node-
positive group (p = 0.0047; Figure 3A), those with either N1
or N2 nodal involvement and R0 resection (0.0092; Figure 3B),
those with N2 nodal involvement and R0 resection (p = 0.0030;
Figure 3D), and those with N1 or N2 node involvement and an
R1 resection (p = 0.0034; Figure 3E), but not in those with N1
nodal involvement and R0 resection (p= 0.707; Figure 3C).
DISCUSSION
During the years of our study 2004–2014, 40,202 patients
underwent SLR, but similar to another recent series of patients
receiving SLR, only a small majority of patients had at least one
lymph node examined, 58.3% in our population and 55.4% in
the past series (11). Then, 2,615 patients or 11.2% of the 23,440
patients having one node examined had at least one pN+. The
percentage of patients with pN+ decreased steadily during the
years of our study from 15.1 to 8.9%. Likewise, the percentage of
pN+ decreased in patients with both N1 and N2 disease.
The propensity match for preoperative factors for pN+ did
not include differentiation because this information is often
not present with biopsies and can be inaccurate. Small biopsies
often contain scant tumor cells, crush artifact, and/or necrosis,
so differentiation is often difficult to obtain (14). We did not
include cN+ in our models because we feel that all clinically
enlarged nodes should be assessed for nodal involvement
prior to consideration of any planned surgical procedure. Our
investigation noted that of the patients presenting with clinically
enlarged nodes, 66.5% had positive nodes. Central location is
a known risk factor for lymph node involvement, but this risk
factor was not readily available for all populations in this large
database, and it should be noted that this definition does vary
in the literature (15). Furthermore, one recent large series of
938 patients noted that those with centrally located tumors
(defined the inner two thirds of the lung on CT) were not at
increased risk of lymph node involvement (16). Our propensity
match noted that white Hispanic patients have an increased
risk of node involvement. There is conflicting literature in
regard to white Hispanic patients’ risk of node involvement
compared to other races (17, 18). We do not know of any
other series that demonstrates that the RUL location has a
lower risk of node involvement except for one series using
the SEER database that demonstrated a significantly lower risk
of node involvement with right upper as compared to right
lower lobe locations (18). Since central location is associated
with a higher chance of lymph node involvement (19) and
this factor is unavailable in NCDB, we speculate that the
RUL location possibly had more tumors located peripherally
within the lung. Of course, smaller tumor size (20) and
BAC have been associated with a lower risk of lymph node
involvement (21). However, it must be acknowledged that
BAC as classified in this database is a heterogeneous category
since a multi-society committee reclassifed BAC into new
categories of adenocarcinoma in situ (AIS), minimally invasive
adenocarcinoma (MIA), invasive lepidic adenocarcinoma, and
invasive mucinous adenocarcinoma (22), so we expect tumors
classified as BAC in our project to represent a heterogeneous
group with a relatively low risk of pN+. Squamous cell carcinoma
was also found to have a lower risk of node involvement as noted
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AGE (/10 years) 1.290 1.153 1.442 < 0.0001
SEX Male vs. Female 1.231 1.086 1.396 0.001
race: Asian or Pacific Islander vs. White Non-hispanic 0.492 0.283 0.855 0.02
race_group5 Other/Unknown vs. White Non-hispanic 0.815 0.639 1.04
race: Other/Unknown vs. White Non-hispanic 0.957 0.761 1.204
race: White Hispanic vs. White Non-hispanic 0.647 0.405 1.036
CDCC: 1 vs. 0 1.174 1.027 1.343 0.03
CDCC: 2 vs. 0 1.209 1.003 1.459
Location: Left lower lobe vs. Right upper lobe 0.975 0.794 1.197 0.84
Location: Left upper lobe vs. Right upper lobe 0.983 0.836 1.155
Location Main bronchus vs. Right upper lobe Undef 0 7.23E +
103
Location: Other/NOS vs. Right upper lobe 1.178 0.842 1.649
Location: Right lower lobe vs. Right upper lobe 1.062 0.878 1.284
Location: Right middle lobe vs. Right upper lobe 1.179 0.842 1.65
histology: Adenosquamous vs. Adenocarcinoma 1.15 0.844 1.567 0.85
histology: BAC vs. Adenocarcinoma 1.136 0.811 1.591
histology: Large cell CA vs. Adenocarcinoma 1.029 0.724 1.463
histology: Non-small-cell carcinoma vs. Adenocarcinoma 1.144 0.868 1.507
histology: Squamous cell CA vs. Adenocarcinoma 1.042 0.889 1.222
Facility_Type: Community cancer program vs. academic/research program 0.992 0.754 1.305 0.56
Facility_Type: Comprehensive community cancer program vs.
Academic/Research program
1.026 0.891 1.182
Facility_Type: Integrated network cancer program vs. Academic/research
program
0.871 0.694 1.092
Facility_Location: East North Central vs. New England 0.996 0.741 1.338 0.47
Facility_Location: East South Central vs. New England 0.912 0.655 1.269
Facility_Location: Middle Atlantic vs. New England 0.9 0.672 1.207
Facility_Location: Mountain vs. New England 0.647 0.409 1.023
Facility_Location: Pacific vs. New England 1.077 0.77 1.506
Facility_Location: South Atlantic vs. New England 1.003 0.752 1.339
Facility_Location: West North Central vs. New England 0.952 0.679 1.335
Facility_Location: West South Central vs. New England 1.061 0.743 1.515
Insurance Status: Unknown vs. Private insurance 1.08 0.571 2.044 0.43
Insurance Status: Medicaid vs. Private insurance 1.134 0.825 1.56
Insurance Status: Medicare vs. Private insurance 0.871 0.732 1.037
Insurance Status: Not Insured vs. Private insurance 0.936 0.564 1.552
INSURANCE_ Other Government vs. Private insurance 1.295 0.694 2.416
Median Income 2012: $38,000–$47,999 vs. <$38,000 0.909 0.749 1.104 0.086
Median Income 2012: $48,000–$62,999 vs. <$38,000 0.9 0.736 1.101
MED_INC_QUAR_ $63,000 + vs. <$38,000 0.767 0.619 0.951
Completely rural or <2,500 urban population, adjacent to a metro area vs.
Counties in metro areas of 1 million population or more
0.639 0.333 1.229 0.36
Completely rural or <2,500 urban population, not adjacent to a metro area
vs. Counties in metro areas of 1 million population or more
1.149 0.627 2.104
Counties in metro areas of 250,000–1 million population vs. Counties in
metro areas of 1 million population or more
1.154 0.981 1.357
Counties in metro areas of fewer than 250,000 population vs. Counties in
metro areas of 1 million population or more
1.103 0.88 1.382
(Continued)
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Urban population of 2,500–19,999, adjacent to a metro area vs. Counties in
metro areas of 1 million population or more
1.19 0.92 1.54
Urban population of 2,500–19,999, not adjacent to a metro area vs.
Counties in metro areas of 1 million population or more
0.867 0.566 1.328
Urban population of 20,000 or more adjacent to a metro area vs. Counties
in metro areas of 1 million population or more
1.074 0.793 1.453
Urban population of 20,000 or more not adjacent to a metro area vs.
Counties in metro areas of 1 million population or more
0.851 0.536 1.351
Surgery: Segmentectomy vs. Wedge resection 0.953 0.822 1.106 0.78
Surgery: Sub-lobar resection, NOS vs. Wedge resection 0.941 0.7 1.264
Tumor Size (/10 cm) 1.057 1.028 1.087 0.0001
Any Pathologically Positive Nodes vs. None 1.102 1.063 1.143 < 0.0001
Nodes examined by pathology 0.968 0.957 0.979 < 0.0001
Year of diagnosis 0.966 0.919 1.016 0.18
Pathological T-Stage: T2 vs. T1 1.208 1.054 1.385 0.009
Pathological T-Stage: T3 vs. T1 1.107 0.869 1.41
Pathological T-Stage: T4 vs. T1 1.46 1.092 1.953
N2 vs. N1 1.291 1.125 1.482 0.0003
Radiation: Any vs. None 1.345 0.905 2 0.14
RAD_REGIONAL_DOSE_cGy Unit = 10,000 0.411 0.194 0.873 0.021
chemo_ Any vs. None 0.777 0.667 0.906 0.001
LVI _ Present vs. Not present 1.446 1.188 1.759 0.001
LVI_ Unknown vs. Not present 1.172 0.945 1.454
GRADE: Cell type not determined, not stated or not applicable, unknown
primaries, high-grade dysplasia vs. well-differentiated, differentiated, NOS
0.928 0.623 1.382 0.010
GRADE: Moderately differentiated, moderately well-differentiated,
intermediate differentiation vs. well-differentiated, differentiated, NOS
1.234 0.922 1.652
GRADE: Poorly differentiated vs. well-differentiated, differentiated,
NOS
1.394 1.04 1.869
GRADE: Undifferentiated, anaplastic vs. well-differentiated, differentiated,
NOS
1.664 0.949 2.919
Hospital readmission: Planned and unplanned readmission within 30 days
of discharge vs. patient not readmitted
1.741 0.543 5.585 0.31
Hospital readmission: Planned readmission within 30 days of discharge vs.
patient not readmitted
1.264 0.908 1.76
Hospital readmission: Unknown if surgery recommended/performed,
unknown if readmitted within 30 days of discharge vs. patient not readmitted
0.84 0.541 1.303
Hospital readmission: Unplanned readmission within 30 days of discharge
vs. patient not readmitted
1.188 0.899 1.571
Surgical Discharge (/day) 1.026 1.018 1.034 < 0.0001
previously (23–25). Comprehensive community cancer centers
had a higher risk of lymph node involvement [odds ratio (OR)
= 1.18] as compared to those undergoing SLRs at an academic
research institution.
In our population of patients with SLR having at least one
node examined, it was noted that the nodal stage was still
predictive of OS, with OS decreasing as pathologic nodal stage
increased. Even after propensity matching the patients with SLR
to those with lobectomy, it was noted that OS with SLR was
significantly less for all pathologic node stages. This indicates
that suboptimal surgery is a major prognostic factor that is
associated with a survival decrement regardless of the extent of
node involvement.
Our PSM for radiation was well-balanced for patients
receiving and not receiving radiation and was matched for
all major prognostic factors including LVI, age, gender,
chemotherapy use, tumor size, T stage, N stage, Charlson
comorbidity status, tumor grade, number of positive nodes,
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FIGURE 2 | Standardized differences before and after propensity matching between the groups receiving and not receiving radiation in patients undergoing sub-lobar
resection with at least one pathologically positive lymph node (pN+).
etc. When analyzed by an adequate radiation dose of >44Gy,
radiation was associated with a significant survival increase in
all patients with pathologically involved nodes, particularly those
with positive margins and N2 involvement. Radiation had no
effect on OS in the patients with margin-negative disease with
pathologic N1 involvement.
The role of postoperative radiation has not been definitely
proven in patients with or without optimal surgical resection.
We know of no other studies assessing the role of radiation
therapy in patients treated with SLR with pN+. There are
currently no recommendations for this situation. Because of
the limited number of patients with SLR who are found
to have positive nodes, the role of radiation in this setting
will likely never be proven. Our investigation has noted that
similar to patients undergoing lobectomy/pneumonectomy, OS
decreases with higher pathologic nodal stage. Because our results
echo the current National Comprehensive Cancer Network
(NCCN) guideline recommendations concerning PORT in
patients receiving optimal surgery, we believe SLR does not
change the current indications for PORT despite the known
inferior OS and local recurrence risk in this situation. The
NCCN guidelines note that PORT appears to improve OS in
patients with N2 disease and/or positive margins but states that
radiation is not recommended for N0 or N1 disease (26). The
PORT meta-analysis (27) of prospective trials using outdated
radiation techniques demonstrated a possible survival benefit
noted in the N2 population (26) in the era prior to the
proven role of adjuvant chemotherapy. Similarly, a retrospective
study-assembled data prior to the proven role of adjuvant
chemotherapy also noted the beneficial effects of radiation on
survival in those having N2 nodal involvement (28). However,
in the setting of adjuvant chemotherapy and better staging, the
beneficial role of radiation in patients having N2 involvement
have been mixed in more recent retrospective studies (29–
31). We speculate that these more modern studies did not
assess patients by factors associated with local recurrence which
caused the variable results. Indeed, one recent retrospective
series noted that node stage was related to distal recurrence
and OS, but not local recurrence (32). In regard to positive
margins, radiation therapy has been suggested to improve OS
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FIGURE 3 | Continued
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FIGURE 3 | Continued
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FIGURE 3 | Overall survival (OS) of the sub-lobar resection (SLR) group with pathologically positive lymph node (pN+) with or without radiation in the entire
node-positive population (A) and in the subgroups with involvement of both N1 and N2 node involvement (B), N1 node involvement (C), N2 node involvement (D),
and with positive surgical margins (E).
whether it is given concurrently or after chemotherapy (33, 34).
Of interest, a recent randomized phase II study assessed the
benefits of postoperative concurrent chemo/radiation vs. post-
operative chemotherapy only in patients undergoing complete
resection [>90% (bi)lobectomy] of N2 involved NSCLC and
noted no OS or disease-free survival benefit to radiation
therapy (35). Due to small patient numbers in our study,
the question of sequencing could not be entertained in
our investigation.
There are many shortcomings with our investigation. The
data used in this study are retrospective, but they cover ∼70%
of all newly diagnosed malignancies in the United States
annually. Important information is missing such as the rationale
for treating these patients with SLR and the presurgical
performance status. Furthermore, it is not known why some
patients received suboptimal doses of radiation. Suboptimal
radiation may have been given due to normal tissue constraints,
tumor progression, or other unknown reasons. Other important
information was missing including pulmonary function tests,
tumor location (central vs. peripheral), pack years of smoking,
extent of preoperative and postoperative workup, and type of
chemotherapy. However, despite the limitations of the data, there
is no other study that we know that assesses the role of radiation
in patients with pathologically positive nodes receiving SLR,
demonstrates the incidence of pN+ in patients undergoing SLR,
and shows the inferior OS of patients with pN+ undergoing SLR
as compared to (bi)lobectomy.
It should be noted that the authors of this manuscript are
not endorsing SLR in patients with pN+. The purpose of our
investigation is to provide guidance when patients fall under
these unique, less than optimal circumstances. Furthermore,
because of the inferior OS associated with SLR as compared to
(bi)lobectomy when pN+, we feel that aggressive surgical staging
prior to surgery can spare this suboptimal outcome, especially
with improving OS noted when consolidative durvalumab
follows chemo/radiation in patients with N2 involvement (36).
CONCLUSIONS
Although the incidence of pathologically positive nodes has been
falling during the years of our study, positive nodes were present
in close to 9% of patients undergoing SLR during the last year
of our study in the small majority of patients who had one or
more nodes examined. Over 40% of patients undergoing SLR had
no nodes examined. Radiation, when given with adequate doses,
appears to improve the OS in patients undergoing SLR with
pathologic nodal positivity, especially in those with N2 nodal
involvement and/or positive margins.
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